| 1. | | Recruiting | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
Conditions: adult solid tumor; Leukemia; Lymphoma |
| 2. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
Condition: unspecified adult solid tumor, protocol specific |
| 3. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Condition: Cancer |
| 4. | | No longer recruiting | Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
Conditions: Brain Tumor; Genetic Condition; Solid Tumor |
| 5. | | No longer recruiting | Calcitriol Plus Dexamethasone in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
Conditions: stage III prostate cancer; stage IV prostate cancer; adenocarcinoma of the prostate; recurrent prostate cancer |
| 6. | | Suspended | Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors
Condition: unspecified adult solid tumor, protocol specific |
| 7. | | Completed | Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Condition: unspecified adult solid tumor, protocol specific |
| 8. | | No longer recruiting | Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors
Condition: unspecified adult solid tumor, protocol specific |
| 9. | | Completed | Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer
Conditions: stage I bladder cancer; stage 0 bladder cancer; recurrent bladder cancer |
| 10. | | No longer recruiting | Gene Therapy in Treating Patients With Advanced Head and Neck Cancer
Conditions: lip and oral cavity cancer; Head and Neck Cancer; Oropharyngeal Cancer |
| 11. | | No longer recruiting | Gene Therapy in Treating Patients With Cancer of The Liver
Conditions: adult primary hepatocellular carcinoma; localized unresectable adult primary liver cancer |
| 12. | | Recruiting | Hepatic Arterial Infusion Plus Internal Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Conditions: localized unresectable adult primary liver cancer; recurrent adult primary liver cancer; adult primary hepatocellular carcinoma |
| 13. | | No longer recruiting | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
Conditions: adult solid tumor; Gastrointestinal Cancer; hematopoietic and lymphoid cancer |
| 14. | | No longer recruiting | Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2
Conditions: recurrent colon cancer; Stage IV rectal cancer; recurrent rectal cancer; stage IV colon cancer |
| 15. | | No longer recruiting | Octreotide and Doxorubicin in Treating Patients With Advanced Cancer
Condition: unspecified adult solid tumor, protocol specific |
| 16. | | Completed | Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors
Condition: unspecified adult solid tumor, protocol specific |
| 17. | | No longer recruiting | Phase I Study of Vaccination With MUC-1 Antigen and Immunologic Adjuvant SB AS-2 in Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer
Conditions: stage I pancreatic cancer; stage II pancreatic cancer; stage IVA pancreatic cancer; stage III pancreatic cancer |
| 18. | | No longer recruiting | Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
Conditions: stage III pancreatic cancer; stage IVB pancreatic cancer; stage II pancreatic cancer; unresectable gallbladder cancer; ... |
| 19. | | Recruiting | Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
Conditions: Scleroderma; Systemic Sclerosis |
| 20. | | Recruiting | Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer
Conditions: adenocarcinoma of the prostate; stage I prostate cancer; stage II prostate cancer |
